{"schema_version":"secwatch.filing_event.v1","accession":"0001000228-23-000024","form_type":"8-K","ticker":"HSIC","cik":"0001000228","company_name":"HENRY SCHEIN INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.508128+00:00","generated_at":"2026-06-15T07:46:40.941857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Henry Schein Q1 revenue down 3.8% to $3.1B; non-GAAP EPS $1.21 vs $1.44; lowers 2023 guidance to $5.18-$5.35","bullets":["GAAP diluted EPS $0.91 vs $1.30; non-GAAP diluted EPS $1.21 vs $1.44.","Net sales $3.1B, down 3.8% YoY; internal sales grew 6.3% ex-PPE and COVID test kits.","Global Medical sales $1.0B down 17.2% (up 4.2% ex-PPE/COVID test kits); Dental $1.9B up 3.8%.","2023 non-GAAP EPS guidance cut to $5.18-$5.35 from prior $5.38; includes $0.05-$0.10 Biotech Dental dilution.","Repurchased 1.2M shares for $100M in Q1; $415M remains authorized for buybacks."],"urls":{"canonical":"https://secwatch.observer/filing/0001000228-23-000024","json":"https://secwatch.observer/filing/0001000228-23-000024.json","markdown":"https://secwatch.observer/filing/0001000228-23-000024.md","text":"https://secwatch.observer/filing/0001000228-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000024/0001000228-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000024/hsic-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:46:40.941857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dec80e5aef2aa16c084bceac27e80016cfb7fbf0","claim":"HENRY SCHEIN INC reported the first quarter ended April 1, 2023 results: revenue $3.1 billion, net income $121 million, EPS $0.91.","evidence_excerpt":"2 exhibit991.htm PRESS RELEASE MAY 9, 2023 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS ● First-quarter 2023 net sales of $3.1 billion decreased 3.8% compared with first-quarter 2022; internal sales increased 6.3% in local currencies excluding sales of personal protective equipment (PPE) products and COVID-19","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000024/0001000228-23-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended April 1, 2023"},{"label":"Revenue","value":"$3.1 billion"},{"label":"Net income","value":"$121 million"},{"label":"EPS","value":"$0.91"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eab6add8e497e39309e1b57ec6f84bc201a8554d","claim":"HENRY SCHEIN INC reported full-year 2023 results: EPS $5.18 to $5.35. Guidance lowered.","evidence_excerpt":"Updating full-year 2023 non-GAAP diluted EPS guidance to $5.18 to $5.35, reflecting an estimated $0.05 to $0.10 first year dilution from the Biotech Dental acquisition","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000024/0001000228-23-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"EPS","value":"$5.18 to $5.35"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}